Molecular Diagnostic Yield of Exome Sequencing in Patients With Cerebral Palsy.

Importance Cerebral palsy is a common neurodevelopmental disorder affecting movement and posture that often co-occurs with other neurodevelopmental disorders. Individual cases of cerebral palsy are often attributed to birth asphyxia; however, recent studies indicate that asphyxia accounts for less than 10% of cerebral palsy cases. Objective To determine the molecular diagnostic yield of exome sequencing (prevalence of pathogenic and likely pathogenic variants) in individuals with cerebral palsy. Design, Setting, and Participants A retrospective cohort study of patients with cerebral palsy that included a clinical laboratory referral cohort with data accrued between 2012 and 2018 and a health care-based cohort with data accrued between 2007 and 2017. Exposures Exome sequencing with copy number variant detection. Main Outcomes and Measures The primary outcome was the molecular diagnostic yield of exome sequencing. Results Among 1345 patients from the clinical laboratory referral cohort, the median age was 8.8 years (interquartile range, 4.4-14.7 years; range, 0.1-66 years) and 601 (45%) were female. Among 181 patients in the health care-based cohort, the median age was 41.9 years (interquartile range, 28.0-59.6 years; range, 4.8-89 years) and 96 (53%) were female. The molecular diagnostic yield of exome sequencing was 32.7% (95% CI, 30.2%-35.2%) in the clinical laboratory referral cohort and 10.5% (95% CI, 6.0%-15.0%) in the health care-based cohort. The molecular diagnostic yield ranged from 11.2% (95% CI, 6.4%-16.2%) for patients without intellectual disability, epilepsy, or autism spectrum disorder to 32.9% (95% CI, 25.7%-40.1%) for patients with all 3 comorbidities. Pathogenic and likely pathogenic variants were identified in 229 genes (29.5% of 1526 patients); 86 genes were mutated in 2 or more patients (20.1% of 1526 patients) and 10 genes with mutations were independently identified in both cohorts (2.9% of 1526 patients). Conclusions and Relevance Among 2 cohorts of patients with cerebral palsy who underwent exome sequencing, the prevalence of pathogenic and likely pathogenic variants was 32.7% in a cohort that predominantly consisted of pediatric patients and 10.5% in a cohort that predominantly consisted of adult patients. Further research is needed to understand the clinical implications of these findings.

[1]  Daniela C. Zarnescu,et al.  Mutations disrupting neuritogenesis genes confer risk for cerebral palsy , 2020, Nature Genetics.

[2]  Steven P. Miller,et al.  Defining the clinical, molecular and imaging spectrum of adaptor protein complex 4-associated hereditary spastic paraplegia. , 2020, Brain : a journal of neurology.

[3]  D. Ledbetter,et al.  Long overdue: including adults with brain disorders in precision health initiatives. , 2020, Current opinion in genetics & development.

[4]  I. Alonso,et al.  GNAO1 mutation presenting as dyskinetic cerebral palsy , 2019, Neurological Sciences.

[5]  S. Scherer,et al.  Meta-analysis and multidisciplinary consensus statement: exome sequencing is a first-tier clinical diagnostic test for individuals with neurodevelopmental disorders , 2019, Genetics in Medicine.

[6]  K. Anagnostopoulou,et al.  The genetic etiology in cerebral palsy mimics: The results from a Greek tertiary care center. , 2019, European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society.

[7]  J. Gécz,et al.  Genetic or Other Causation Should Not Change the Clinical Diagnosis of Cerebral Palsy , 2019, Journal of child neurology.

[8]  E. Bertini,et al.  Phenomenology and clinical course of movement disorder in GNAO1 variants: Results from an analytical review. , 2019, Parkinsonism & related disorders.

[9]  C. Fairhurst,et al.  Cerebral palsy in adults: summary of NICE guidance , 2019, BMJ.

[10]  T. Loddenkemper,et al.  Diagnostic yield of genetic tests in epilepsy , 2019, Neurology.

[11]  J. Gécz,et al.  Pathogenic copy number variants that affect gene expression contribute to genomic burden in cerebral palsy , 2018, npj Genomic Medicine.

[12]  A. Ekici,et al.  The mutational and phenotypic spectrum of TUBA1A-associated tubulinopathy , 2018, bioRxiv.

[13]  N. Paneth,et al.  The complex aetiology of cerebral palsy , 2018, Nature Reviews Neurology.

[14]  K. Nakayama,et al.  Genomic analysis identifies masqueraders of full‐term cerebral palsy , 2018, Annals of clinical and translational neurology.

[15]  S. Scherer,et al.  De novo and rare inherited copy-number variations in the hemiplegic form of cerebral palsy , 2017, Genetics in Medicine.

[16]  Sarah McIntyre,et al.  Early, Accurate Diagnosis and Early Intervention in Cerebral Palsy: Advances in Diagnosis and Treatment , 2017, JAMA pediatrics.

[17]  D. Pilz,et al.  Clinical features associated with CTNNB1 de novo loss of function mutations in ten individuals. , 2017, European journal of medical genetics.

[18]  Marylyn D. Ritchie,et al.  Distribution and clinical impact of functional variants in 50,726 whole-exome sequences from the DiscovEHR study , 2016, Science.

[19]  W. Chung,et al.  Clinical application of whole-exome sequencing across clinical indications , 2015, Genetics in Medicine.

[20]  Stephen J. Blumberg,et al.  Prevalence of cerebral palsy and intellectual disability among children identified in two U.S. National Surveys, 2011-2013. , 2016, Annals of epidemiology.

[21]  Christa Lese Martin,et al.  A Cross-Disorder Method to Identify Novel Candidate Genes for Developmental Brain Disorders. , 2016, JAMA psychiatry.

[22]  D. Ledbetter,et al.  The Geisinger MyCode Community Health Initiative: an electronic health record-linked biobank for Precision Medicine research , 2015, Genetics in Medicine.

[23]  E. Flachs,et al.  Predictors for early diagnosis of cerebral palsy from national registry data , 2015, Developmental medicine and child neurology.

[24]  John Wei,et al.  Clinically relevant copy number variations detected in cerebral palsy , 2015, Nature Communications.

[25]  D. Lev,et al.  Copy number variations in cryptogenic cerebral palsy , 2015, Neurology.

[26]  H. Rehm,et al.  Standards and Guidelines for the Interpretation of Sequence Variants: A Joint Consensus Recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology , 2015, Genetics in Medicine.

[27]  R A Gibbs,et al.  Whole-exome sequencing points to considerable genetic heterogeneity of cerebral palsy , 2015, Molecular Psychiatry.

[28]  G. Rouleau,et al.  De Novo Mutations in the Motor Domain of KIF1A Cause Cognitive Impairment, Spastic Paraparesis, Axonal Neuropathy, and Cerebellar Atrophy , 2015, Human mutation.

[29]  Siddharth Srivastava,et al.  Clinical whole exome sequencing in child neurology practice , 2014, Annals of neurology.

[30]  I. Krägeloh-Mann,et al.  What constitutes cerebral palsy in the twenty‐first century? , 2014, Developmental medicine and child neurology.

[31]  E. Haan,et al.  Rare copy number variation in cerebral palsy , 2013, European Journal of Human Genetics.

[32]  J. Fink,et al.  Hereditary spastic paraplegia: clinico-pathologic features and emerging molecular mechanisms , 2013, Acta Neuropathologica.

[33]  David W. Evans,et al.  Developmental brain dysfunction: revival and expansion of old concepts based on new genetic evidence , 2013, The Lancet Neurology.

[34]  J. Ellenberg,et al.  The association of cerebral palsy with birth asphyxia: a definitional quagmire , 2013, Developmental medicine and child neurology.

[35]  G. Gyapay,et al.  KIF1A missense mutations in SPG30, an autosomal recessive spastic paraplegia: distinct phenotypes according to the nature of the mutations , 2012, European Journal of Human Genetics.

[36]  D. Ledbetter,et al.  Genetic insights into the causes and classification of the cerebral palsies , 2012, The Lancet Neurology.

[37]  D. Ledbetter,et al.  Adaptor protein complex-4 (AP-4) deficiency causes a novel autosomal recessive cerebral palsy syndrome with microcephaly and intellectual disability , 2010, Journal of Medical Genetics.

[38]  B. Dan,et al.  A report: the definition and classification of cerebral palsy April 2006 , 2007, Developmental medicine and child neurology. Supplement.

[39]  J. Fink,et al.  De novo occurrence of novel SPG3A/atlastin mutation presenting as cerebral palsy. , 2006, Archives of neurology.